Sigma Healthcare's (ASX:SIG) fiscal first-half results were strong, met expectations, and showed that costs were well managed, according to a Thursday note by Jarden Research.
On Thursday, the company reported fiscal first-half normalized earnings of AU$0.034 per share and revenue of AU$5.51 billion.
The company also reported a "very strong" trading update, with second half year-to-date sales up 16.6% across Chemist Warehouse, and ahead of Jarden's expectations.
The investment firm reaffirmed an overweight rating and AU$3.60 price target on Sigma Healthcare.
Shares of Sigma Healthcare rose 2% in recent Thursday trade.